Alexander's Inc.: Numerous Signs Of Distress
Office REITs have gained modestly this year, but face challenges due to the WFH trend and mounting defaults in commercial real estate loans. Alexanders, Inc. is a small-cap REIT with a portfolio of office and retail properties in New York City, facing heavy indebtedness, shrinking revenues, and reliance on a single tenant. ALX faces liquidity issues, and may need to cut dividends or dilutively issue new shares, making it a risky investment for the longer term.
Three Office REITs To Sell With Weak Balance Sheets
There will likely be a major sell-off in REITs in the next 2-5 years. Weak REITs with messy balance sheets, weak forecasts for FFO growth, unsafe dividends, and/or overvaluation are likely to suffer the most damage in any downturn. This article focuses on three specific REITs that may be particularly vulnerable in a downturn.
ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
ALX Oncology valuation has dropped below $500 million, presenting new studies at venues like ASCO, reaching a point of inflection. Evorpacept is the main focus, showing promising activity signals in gastric cancer and urothelial carcinoma, with upcoming data updates and trials. Financially, ALXO has a reasonable cash pool to fund operations for the near term, with a runway of 5-6 quarters.
The Ultimate Contrarian Plays: 7 Hated Stocks Yielding Up To 12.9%
What's better than a big dividend?
